Objectives: The aim of this study was to investigate whether dendritic cells (DCs) transfected with human secondary lymphoid-tissue chemokine (hSLC) and human interleukin-2 (hIL-2) genes are capable of improving DC's proliferation and to produce a marked antitumor effect in vitro combined with T-lymphocyte (TC).
Methods: SLC gene primer was designed based on the corresponding gene sequence in GenBank. The Kpn I site was introduced into the upstream of the primer and Xho I site into the downstream. The SLC gene was amplified with the template of pET32a(+)-SLC by polymerase chain reaction. SLC was cloned into pBudCE4.1/IL-2 (TRAIL was cut from pBudCE4.1/TRAIL- IL-2 before) to construct recombinant plasmid pBudCE4.1/SLC-IL-2(PSI). DCs were transfected with pBudCE4.1/SLC-IL-2 by gene electric transfection. Protein expression was determined with Western blot and enzyme-linked immunosorbent assays. Cytotoxicity of TC and DC against the human bladder tumor cell were examined by chromium release assay. Flow cytometric analyses were performed to determine the apoptosis of tumor cells and the percentage of Treg.
Results: A high level of expression of SLC and IL-2 was observed in DCs transfected with SLC and IL-2 genes. The mean production of IL-2 was 19.8 +/- 2.5, 511.10 +/- 52.36, and 541.3 +/- 62.04 ng/10(6) cells/24 hours in the DC/vector, DC/IL-2, and DC/SLC-IL-2, respectively. The mean SLC production was 29.8 +/- 4.43, 506.10 +/- 42.36, and 567.34 +/- 52.05 ngs/10(6)cells/24 hours in the DC/ vector, DC/SLC, and DC/SLC-IL-2, respectively. Cytotoxicity to bladder cancer cells was increased. The mean cytotoxicity (the effector/target ratio, 40:1) of TC-DC/parental, TC-DC/IL-2, TC-DC/SLC, and TC-DC/SLC-IL-2(TDSI) to the human bladder cancer cells was 32.1 +/- 5.5%, 63.5 +/- 6.6%, 78.1 +/- 9.63%, respectively. The apoptotsis rate of bladder cancer cells treated with TDSI was 18.6% by flow cytometry. Treg cells' percentage was very small in the DC medium.
Conclusions: SLC and IL-2 were produced by autocrine in DCs transfected with SLC and IL-2 genes. DC/SLC-IL-2 can promote DC proliferation, while TC-DC/SLC-IL-2 and TC-DC/SLC could strongly enhance significant cytotoxicity against bladder cancer cell that was induced by the coculture of DCs (transfected with SLC and IL-2) and TC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/07357900802375746 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fluorinated polyethyleneimine vectors with serum resistance and adjuvant effect to deliver LMP2 mRNA vaccine for nasopharyngeal carcinoma therapy.
Acta Biomater
December 2024
State Key Laboratory in Quality Research of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, 999078, PR China; MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, 999078, PR China. Electronic address:
Latent membrane protein 2 (LMP2), which is an important protein of Epstein-Barr virus (EBV) in the latent phase to mediate metastasis and recurrence, has shown great potential as a targeting antigen in mRNA vaccine for nasopharyngeal carcinoma (NPC) therapy. In this study, an LMP2 mRNA vaccine was developed based on a serum-resistant fluorinated polyethyleneimine (PF) with the self-adjuvant effect for achieving a strong anti-tumor immunity in NPC treatment. Specifically, the proposed vaccine PEG[PF/mLMP2] was comprised of a PF/mLMP2 core formed by the cationic PF and LMP2 mRNA, together with a dialdehyde poly (ethyl glycol) (OHC-PEG-CHO) coating.
View Article and Find Full Text PDFDistinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response.
ACS Nano
December 2024
Department of Surgery; Larner College of Medicine, University of Vermont, Burlington, Vermont 05405, United States.
Developments in mRNA/lipid nanoparticle (LNP) technology have advanced the fields of vaccinology and gene therapy, raising questions about immunogenicity. While some mRNA/LNPs generate an adjuvant-like environment in muscle tissue, other mRNA/LNPs are distinct in their capacity for multiple rounds of therapeutic delivery. We evaluate the adjuvancy of components of mRNA/LNPs by phenotyping cellular infiltrate at injection sites, tracking uptake by immune cells, and assessing the inflammatory state.
View Article and Find Full Text PDFNasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model.
Int J Nanomedicine
November 2024
Department of Thoracic Surgery, Shanghai Ninth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Article Synopsis
- Lung metastasis is a major cancer-related death cause, but mRNA-based vaccines and intranasal immunization show promise in targeting lung tumors.
- Researchers developed a novel mRNA nanovaccine that effectively activates immune cells, enhancing their ability to fight cancer.
- In mouse models, this nanovaccine significantly reduced lung metastasis and improved therapeutic outcomes by boosting the immune response through targeted delivery to the lungs.
Enhanced gene transfection ability of sulfonylated low-molecular-weight PEI and its application in anti-tumor treatment.
J Mater Chem B
November 2024
Key Laboratory of Green Chemistry and Technology (Ministry of Education), College of Chemistry, Sichuan University, Chengdu 610064, P. R. China.
Article Synopsis
- Continuous advancements in nanotechnology are enhancing tumor vaccines and immunotherapy, making them key for cancer treatment.
- A new small-molecule-modified polymer named Ns-P has been developed to effectively deliver antigen-encoding DNA to immune cells, showing high efficiency and low toxicity.
- Ns-P, combined with oxidized mannan, improves biocompatibility and increases uptake by dendritic cells, resulting in stronger immune responses against tumors in mouse models.
Dendritic cell-derived lncRNAs in patients with acute coronary syndrome.
J Cell Mol Med
October 2024
Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Article Synopsis
- Long non-coding RNAs (lncRNAs) and dendritic cells (DCs) are important in understanding acute coronary syndrome (ACS), but their specific mechanisms are not well understood.
- The study analyzed the expression of lncRNAs in monocyte-derived DCs from ACS patients, revealing significant differences in marker expression and inflammatory responses based on the ACS type.
- Findings suggest that lncRNAs, especially CCL15 and CCL14, influence the function of moDCs, highlighting their potential as diagnostic and therapeutic targets for ACS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!